EMERGE Health's Nitisinone (Disanit) for hereditary tyrosinemia type-1 has been granted designated orphan status by the Therapeutic Goods Administration.
Two other additions in the last few days are Eisai's Lenvatinib for the treatment of hepatocellular carcinoma and Amgen's Romiplostim (Nplate) for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
See details at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 17